22 November 2024
: Case report 
Multidrug-Resistant Elizabethkingia meningoseptica and Enterococcus faecium Infection in an Oncohematologic Patient
Patient complains / malpractice
Cristina Motta Ferreira1ACDEF*, Maria De Nazare Saunier Barbosa2BD, Guilherme Motta Antunes Ferreira3BF, Joseir Saturnino Cristino4CDE, Chesman Da Silva Alves3DF, Erasmo dos Santos Vieira3BF, Larissa Alves Gomes5B, Vander Silva Souza1B, Franceline Oliveira Calheiros1B, William Antunes Ferreira6ACDEFDOI: 10.12659/AJCR.945360
Am J Case Rep 2024; 25:e945360
Table 1. Susceptibility test results.
| VITEK-2 equipment | |||||
|---|---|---|---|---|---|
| E. meningoseptica1 | E. faecium1 | ||||
| Antibiotic | MIC (µg/mL) | Interpretation | Antibiotic | MIC (µg/mL) | Interpretation |
| Ampicillin | ≤32 | R | Ampicillin | ≤32 | R |
| Amox+clavulanic acid | ≤32 | R | Levofloxacin | ≤8 | R |
| Pip/tazobactam | ≤128 | R | Linezolid | ≤2 | S |
| Cefuroxime | ≤64 | R | Teicoplanin | ≤32 | R |
| Axetil cefuroxime | ≤64 | R | Vancomycin | ≤32 | R |
| Ceftriaxone | ≤64 | R | Tigecycline | ≥0.12 | S |
| Cefepime | ≤64 | R | – | – | – |
| Ertapenem | ≤8 | R | – | – | – |
| Meropenem | ≤16 | R | – | – | – |
| Amikacin | ≤16 | R | – | – | – |
| Gentamicin | ≤16 | R | – | – | – |
| Ciprofloxacin | 0.5 | S | – | – | – |
| Norfloxacin | 4 | S | – | – | – |
| Nitrofurantoin | ≤512 | R | – | – | – |
| Interpretation: R – resistant; S – sensitive. (–) No interpretative minimum inhibitory concentration (MIC) breakpoints are currently available. BrCAST 2022; CLSI, 2022 guidelines. | |||||
| E-TEST for glycopeptides – E. faecium2 | |||||
| Antibiotic | MIC | Interpretation | |||
| Vancomycin | ≤256µg/mL | R | |||
| Teicoplanin | ≤256µg/mL | R | |||
| Interpretation: R – resistant; S – sensitive. (–) No interpretative minimum inhibitory concentration (MIC) breakpoints are currently available. BrCAST 2022; CLSI, 2022 guidelines. | |||||